
Safety and Efficacy of BAT8006 in combination with BAT1308 in Patients with Advanced Endometrial Cancer

Xingtao Long[1], Yi Gong[1], Yibiao Chen[2], Jiandong Tong[3], Funan Liu[4], Liang Chen[5], Juan Li[5], Hongwei Zhao[6], Xin Wang[6], Guiling Li[7], Danbo Wang[8], Keqiang Zhang[9], Hui Zhang[10], Hui Qiu[11], Tianmin Xu[12], Qi Zhou[1#]


[1]Cho020.00.649q6(X)6githg T(e0.00rsi(, ty)8(C5(ia)-(ia)ce0.00r)21)4sp, Jiag Cho020.00.649q6(X)6gith[,)Chi20.005(ia);[,)]TJETQq0.000014305 0 960 540 reW*nBT/F2

Background

- BAT8006 is a folate receptor alpha (FRα)–targeted ADC consisting of three components: a recombinant humanized anti-FRα antibody, a cleavable linker, and the small-molecule drug exatecan. The drug-to-antibody ratio (DAR) stands 7~8.
- After binding to FRα on tumor cells, BAT8006 is internalized to release exatecan, which inhibits DNA topoisomerase I and induces tumor cell apoptosis.
- Released exatecan from apoptotic tumor cells can also kill neighboring tumor cells via the bystander effect.



- BAT1308 is a recombinant fully human IgG4 anti-PD-1 monoclonal antibody produced in CHO cells by recombinant DNA technology and purified from clarified culture supernatant.
- By binding PD-



Study Design

Demographic and Clinical Characteristics

- A total of 54 EC participants, regardless of FRα expression, with at least 1 prior lines of therapy, were enrolled in this study.

ipants had received prior platinum-based chemotherapy, and 53.7% (29/54) had been treated with prior immunotherapy.

, 36 participants were assigned to the 76 mg/m² group and 18 participants to the 84 mg/m² group.


Efficacy Outcomes in EC Participants

- As of April 20, 2026, a total of 30 participants in the 76 mg/m² group and 17 participants in the 84 mg/m² group were evaluab

Efficacy Outcomes in EC Participants

- With a median follow-up of 3.81 months, the mPFS in 84 mg/m² group was 4.11 months (1.48 to NR), while the mPFS in 76 mg/m² group was 8.11 months (3.84 to NR).
- Due to the short follow-up period to date, OS data have not matured.

K-M Curves of PFS in EC Participants



Swimmer Plot for Tumor Response Evaluation




Overall Safety Results

- As of April 20, 2026, 101 participants with advanced solid tumors have been enrolled in this study. Of these, 6 participants were enrolled in the 93 mg/m² dose group during the dose-escalation phase only, while 55 participants were enrolled in the 76 mg/m² dose group and 40 participants in the 84 mg/m² dose group.
- In dose-escalation phase, no (0/6) DLT were observed at 76 mg/m² dose level. One (1/6) DLT were observed at 84 mg/m² dose level. Two (2/6) DLTs were observed at 93 mg/m² dose level.
- The most common Grade ≥3 TEAEs were white blood cell count decreased, neutrophil count decreased, anaemia and platelet count decreased. These hematologic toxicities were clinically manageable and associated with favorable outcomes.

Safety Summary in Advanced Solid Tumor

	76 mg/m² (n=55)	84 mg/m² (n=40)
Any TEAEs	52 (94.5%)	40 (100%)
Grade 3 TEAEs	37 (67.3%)	32 (80.0%)
Grade 3 TRAEs	37 (67.3%)	31 (77.5%)
SAE	23 (41.8%)	21 (52.5%)
irAE	5 (9.1%)	6 (15%)
TEAEs leading to study drug dose reduction	10 (18.2%)	14 (35.0%)
TEAEs leading to study drug discontinuation	5 (9.1%)	4 (10.0%)
TRAEs leading to death	0	0

Most common Grade 3 TEAEs



Conclusions

- The safety profile of BAT8006 in combination with BAT1308 was generally tolerable, with no identified safety signals indicative of ILD or ocular toxicity. The main adverse events were hematologic toxicities, which w(rse r)-7pre(di)3(traber)-8

ins(evriety)73(8)]TJETQ EMC /P /MCID54/Lang (en-US)>BDC q0.000014305 0 960

Acknowledgements

- We extend our deepest gratitude to all the patients who participated in this study and their families for their invaluable contribution and unwavering support.
- Our sincere thanks also go to the investigators and staff at the participating study sites for their dedication and hard-work in the successful execution of this trial.
- This study was made possible by the support of Bio-Thera Solution Co., Ltd.